clinical trial · NCT07144111
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Genentech, Inc.·phase1·recruiting·n = 32
Hepatic ImpairmentInavolisib
brief summary
This open-label study will evaluate the effect on the pharmacokinetics (PK), safety, and tolerability of a single oral dose of inavolisib in participants with moderate or severe hepatic impairment compared with demographically matched healthy participants with normal hepatic function.
started
Aug 21, 2025
primary completion
Sep 4, 2026
completion
Sep 6, 2026
last updated
Jun 8, 2026
official title
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics of Inavolisib
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol